Tech Company Financing Transactions
Neurosterix Funding Round
On 4/4/2024, Neurosterix landed $63 million in funding from Perceptive Xontogeny Venture Fund, Acorn Bioventures and Perceptive Advisors.
Transaction Overview
Company Name
Announced On
4/4/2024
Transaction Type
Venture Equity
Amount
$63,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
9 Chemin Des Mines
Geneva, 1202
Switzerland
Geneva, 1202
Switzerland
Phone
Undisclosed
Website
Email Address
Overview
Neurosterix is a biopharmaceutical company focused on developing allosteric modulators for the treatment of neurological disorders. Our drug discovery and development platform identifies and develops allosteric modulators -- molecules that increase or decrease the activity of target receptors by binding outside of the "active site" where endogenous ligands and traditional drugs operate. Through this platform, Neurosterix's novel drug candidates have the potential to provide medicines with improved efficacy, safety and tolerability for patient communities suffering from underserved neurological disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Tim Dyer
Browse more venture capital transactions:
Prev: 4/3/2024: Full Glass Wine venture capital transaction
Next: 4/4/2024: ikas venture capital transaction
Share this article
Where The Data Comes From
We do our best to document tech company VC transactions. All VC database entries reported here are derived from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs